Incyte Corporation
Incyte Corporation works on 19 rare diseases tracked on Trial Friend, including Aplastic Anemia, Cholangiocarcinoma, Chronic Graft-versus-Host Disease and 16 more, with 41 active clinical trials (30 recruiting) and 4 FDA-approved rare disease drugs.
Incyte Corporation develops targeted therapies for rare blood cancers, graft-versus-host disease, and other rare hematologic and immunologic conditions. Key products include Jakafi (ruxolitinib), a JAK inhibitor approved for myelofibrosis, polycythemia vera, acute graft-versus-host disease, and chronic graft-versus-host disease; Pemazyre (pemigatinib) for cholangiocarcinoma; and NIKTIMVO (axatilimab), an anti-CSF1R antibody approved in 2024 for chronic graft-versus-host disease.
Focus areas at Incyte Corporation
Within its broader pharmaceutical portfolio, Incyte Corporation has active clinical trial programs and drug development efforts across 19 rare diseases, including Aplastic Anemia, Cholangiocarcinoma, Chronic Graft-versus-Host Disease, Essential Thrombocythemia, Fibrodysplasia Ossificans Progressiva, and 14 additional rare conditions. These programs may span orphan drug designation, novel therapeutic mechanisms, and precision medicine approaches targeting the underlying causes of each disease.
The clinical trials section below shows active and recruiting rare disease studies sponsored by Incyte Corporation, sourced live from ClinicalTrials.gov. Each trial includes its current recruitment status, study phase (Phase 1 through Phase 4), conditions under investigation, and the number of active trial sites. The FDA-approved drugs section lists treatments that have received U.S. Food and Drug Administration approval, with brand names, generic names, approval dates, and matched rare disease indications from the openFDA database.
Incyte Corporation is headquartered in Wilmington, United States, founded in 1991, publicly traded under the ticker symbol INCY. The company maintains a dedicated rare disease division alongside its broader therapeutic portfolio, working to bring innovative treatments to patients with conditions that have historically had limited or no treatment options.
Incyte Corporation Drug Pipeline
Incyte Corporation has 41 active clinical trials across 4 development stages, with 30 currently recruiting participants. Clinical trials advance through phases: Phase 1 tests safety in a small group, Phase 2 evaluates effectiveness and side effects, Phase 3 confirms benefit in a larger population, and Phase 4 monitors long-term safety after FDA approval.
Note: This pipeline counts the active and recruiting trials listed on this page, from ClinicalTrials.gov. For companies that work outside rare disease, we list only trials for rare diseases we track, so the company's full pipeline may be larger.
Incyte Corporation Clinical Trials (41)
Active and recruiting clinical trials sponsored by Incyte Corporation, sourced live from ClinicalTrials.gov. Each trial card shows the study phase, current recruitment status, conditions under investigation, study locations, eligibility criteria, and a direct link to the full ClinicalTrials.gov record. You can also download a one-page PDF summary to share with your doctor.
Note: Recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator.
Pick a condition. One email when a new trial opens, a trial changes or the FDA decides, from any company, not only Incyte Corporation. Unsubscribe anytime.
You'll get new recruiting trials, changes to trials, FDA decisions and condition news for Aplastic Anemia. Turn any of these off from the link in every email.
Incyte Corporation FDA-Approved Drugs (4)
Medications developed or marketed by Incyte Corporation that have received U.S. Food and Drug Administration approval. Drug data is sourced from the openFDA database and includes brand names, generic names, approval dates, and matched rare disease indications. Where a drug treats a condition covered by Trial Friend, the disease name links directly to that disease page.
| Drug Name | Brand Name | Rare Diseases | Approval Date |
|---|---|---|---|
| RUXOLITINIB Kinase Inhibitor [EPC] | JAKAFI oral | Nov 16, 2011 | |
| AXATILIMAB | NIKTIMVO | Aug 14, 2024 | |
| PEMIGATINIB Kinase Inhibitor [EPC] | PEMAZYRE oral | Apr 17, 2020 | |
| RETIFANLIMAB-DLWR | ZYNYZ | Mar 22, 2023 |
Incyte Corporation Trial Locations
Incyte Corporation clinical trials are running at 703 sites in 28 countries. Click any country to drill down by state, city, and individual research facility. Proximity to a trial site is one of the most important factors in deciding whether to participate.
Rare Disease Focus Areas (19)
Diseases targeted by Incyte Corporation's clinical trial and drug development programs
Aplastic anemia is a rare bone marrow failure syndrome characterized by pancytopenia resulting from absent or severely reduced hematopoiesis. Approximately half are immune-mediated, while others resul...
Cholangiocarcinoma is a rare and aggressive cancer that forms in the bile ducts, the thin tubes that carry digestive fluid (bile) from the liver to the small intestine. It can occur inside the liver (...
Chronic graft-versus-host disease is an immune-mediated complication after allogeneic stem cell or bone marrow transplant, in which donor immune cells attack the recipient's tissues. It can affect the...
Essential Thrombocythemia is a myeloproliferative neoplasm characterized by overproduction of platelets by bone marrow, resulting in very high platelet counts. Patients are at increased risk for blood...
Fibrodysplasia Ossificans Progressiva (FOP) is an extremely rare genetic disorder characterized by progressive heterotopic ossification, where soft tissues (muscles, tendons, ligaments) gradually tran...
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract, arising from the interstitial cells of Cajal or their precursors. Most GISTs are driven by...
Patient Resources
Organizations and resources related to Incyte Corporation's rare disease focus areas
Frequently Asked Questions About Incyte Corporation
Common questions about Incyte Corporation's rare disease programs, clinical trials, and treatments.